Background and activities
Research Scientist at Centre of Myeloma Research the Department of Cancer Research and Molecular Medicine.
Multiple myeloma is a type of cancer that begins in plasma cells, which are the antibody-producing cells of the immune system. A characteristic for multiple myeloma is that the malignant plasma cells, except during the very last stages of the disease, are found within the bone marrow. It is generally believed that growth and survival of myeloma cells is critically dependent on the bone marrow microenvironment. My main focus is to examine the interplay between the bone marrow microenvironment and the myeloma cells. I perform drug sensitivity testing of myeloma cells, and do these experiments in co-cultures, where myeloma cells are cultured together with bone marrow stromal cells, in an attempt to mimicking aspect of the bone marrow microenvironment. We study the interaction between myeloma cells and stromal cells, and look at mechanism involved in the stroma-protective effect on myeloma cell viability and in their resistance to some common drugs.
I am also involved in the “Personalized cancer medicine” project at the Norwegian Cancer Genomics Consortium, for Multiple Myeloma. In this project we will perform whole exome sequencing on primary myeloma cells. One goal is to detect important driver mutations in individual myeloma patients, and hopefully these mutation profiles can be important for therapeutic decisions. More info about this project: http://cancergenomics.no/index.php?page=home
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
- (2017) Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. vol. 102 (7).
- (2016) Src family kinases are regulated in multiple myeloma cells by phosphatase of regenerating liver-3. Molecular Cancer Research. vol. 15 (1).
- (2016) Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. OncoTarget. vol. 7 (43).
- (2016) Complementary Activation of CCND, MYC, RAS and NFkB by Mutations in Multiple Myeloma. Blood. vol. 128 (22).
- (2016) The phosphatase of regenerating liver-3 (PRL-3) is importantfor IL-6-mediated survival of myeloma cells. OncoTarget. vol. 7 (19).
- (2016) Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells. Blood Cancer Journal.
- (2016) Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro. Journal of Hematology & Oncology. vol. 9 (75).
- (2015) The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Scientific Reports. vol. 5:13001.
- (2015) MYC amplifications in myeloma cell lines: Correlation with MYC-inhibitor efficacy. OncoTarget. vol. 6 (26).
- (2015) The marine n-3 PUFA DHA evokes cytoprotection against oxidative stress and protein misfolding by inducing autophagy and NFE2L2 in human retinal pigment epithelial cells. Autophagy. vol. 11 (9).
- (2015) Chloroquine potentiates Carfilzomib but not Bortezomib effects on myeloma cells. Cancer Research.
- (2015) Detection and Monitoring of BRAF and NRAS Mutant Clones in Myeloma Patients By Digital PCR of Circulating DNA. Blood. vol. 126 (23).
- (2015) BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal. vol. 5:e299 (3).
- (2015) Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. OncoTarget. vol. 6 (32).
- (2014) MYC gene copy number determine MYC expression and sensitivity to a MYC-inhibitor in multiple myeloma cells. Cancer Research. vol. 74.
- (2014) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal. vol. 4.
- (2014) PRL-3 Mediates Survival of Primary Myeloma Cells. Blood. vol. 124.
- (2014) Salt-inducible kinase 1 (SIK1) is induced by gastrin and inhibits migration of gastric adenocarcinoma cells. PLoS ONE. vol. 9 (11).
- (2013) Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway. Cancer Letters. vol. 335 (2).
- (2013) Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. European Journal of Haematology. vol. 91 (4).